Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
Advertisement
Amylin Pharmaceuticals, Inc. announced that it has filed a preliminary prospectus supplement to its shelf registration statement with the Securities and Exchange Commission relating to a proposed underwritten public offering of 6.5 million shares of its common stock. To the extent that the underwriters sell more than 6.5 million shares, the company also will grant an over- allotment option to the underwriters for the purchase of up to an additional 975,000 shares of common stock. All of the shares are being sold by Amylin Pharmaceuticals.